Thomas Hadley Email & Phone Number

Altrincham, England, Gb

UTILITY therapeutics is focused on developing and commercializing antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. Reporting directly to the Board of Directors – responsible for advancing an antibiotic portfolio to NDA, commercialization, capital raise, business development, and securing banking advisor.• Managed the development of PIVYA NDA and FDA interactions which led to FDA approval of PIVYA• PIVYA is now the 1st New FDA approved antibiotic for uncomplicated UTIs in over 20 years

Washington, Dc, Us

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 3 FDA-approved sustained-release treatments in ophthalmology.• Hired and launched new team of Strategic Account Managers to expand utilization of DEXYCU and YUTIQ• Launched innovative reimbursement program to minimize financial exposure for ASCs, PEs, and PM Companies• Developed detailed analytics to identify key areas of growth for DEXYCU

• Built Commercial infrastructure inclusive of Marketing, Sales, Sales Ops, Analytics and Trade personnel• Developed strategy and executed the launches of 2 innovative Ophthalmic brands in Q1, 2019 in 2 distinct TAs with 2 distinct sales forces• Manage Manufacturing, Distribution, and forecasting Demand for the organization

Dublin, Ireland, Ie

Horizon Pharma plc is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, primary care and rheumatology business units. Horizon’s global headquarters are in Dublin, Ireland.Responsible for the full P&L of the BU. Charged with growing the 2015 sales of $500M by 20+% through organic growth, and innovative strategies to $600M+ in 2016 within budget. Managing a sales team of 380 Sales representatives/Key Account Managers and 5 Brand Managers with responsibility for 3 marketed Brands. Directing all sales and marketing initiatives to meet and exceed ambitious sales goals.

Responsible for the integration of the Salix marketing department into the Valeant organization. Charged with growing the current sales of $1.5B by 30%+ through organic growth, product launches, and acquisitions in 2015. Managing a team of 10 marketers with responsibility for 7 marketed Brands including one orphan drug, and 10+ de-prioritized products, directing all marketing initiatives, including but not limited to: Professional, Medical Marketing, DTC, Digital, LCM, and growth strategies to meet and exceed ambitious sales goals. Developing, testing, and measuring marketing and promotional campaigns to ensure engagement by both target Consumers and Healthcare professional audiences.

Leading the development and execution of the US strategic business for the launch of JUBLIA (efinaconazole 10% solution) in the topical anti-fungal market. Responsibilities include professional and consumer campaign development (TV, Print, Digital), KOL advocacy and market development, managed care access, trade pull through as well as forecasting.

Napa, Ca, Us

Governed global marketing initiatives for $600M+ EpiPen business channel. Defined division priorities, analyzed market trends for areas of opportunity, and crafted growth strategies to meet and exceed ambitious sales goals. Led relations with key opinion leaders, helping to spur product demand, interest, and endorsement among top-tier industry professionals. Designed and implemented marketing and promotional campaigns to engage both target consumers and Healthcare professional audiences.

Rahway, New Jersey, Us

Formulated, developed, and implemented marketing strategies to drive growth. Employed market, consumer, and industry research to inform Go-To-Market strategies and position Merck as global leader in innovative contraception technologies and products. Led the efforts of multiple Director-level marketers within a matrixed organization and aligned all key stakeholders around common strategy to meet yearly objectives.

Rahway, New Jersey, Us

Schering-Plough was acquired by Merck in 2009 for $41B, creating one of the world’s largest pharmaceutical companies with over $48B in annual revenue. Led a cross-functional team in the creation and execution of a new global brand vision, positioning, personality, creative concept, and message flow for NuvaRing. Identified and captured opportunities to further distinguish NuvaRing in product concept and messaging, and strengthened brand recognition and preference on a global scale.

Rahway, New Jersey, Us

Organon International was the human pharmaceutical unit of Netherlands-based Asko Nobel; the company was acquired by Schering-Plough in 2007 for $14.4B, forming a pharmaceutical leader with over $18B in annual revenue.Directed the efforts of a multi-national team, leading Global Marketing Directors in both the Netherlands and U.S. in the discovery, development, and implementation of global growth strategies. Helped steer product development efforts and established both short- and long-term strategic vision.

Progressed through roles of increasing scope and responsibility, ultimately serving as Executive Director of Marketing, Professional Communications. Drove products from clinical trials through launch, incorporating analysis of market conditions and competitor activity into R&D efforts. Helped design integrated marketing and communication campaigns to build product awareness and showcase product strengths and competitive advantage.

Bs, Marketing/Marketing Management, General

High School